PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DR26FP8QT4570517537!cosentyx unoready 300 MG PEN 2ml — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DR25D3005. PoP ended Jan 15, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Amerisourcebergen Drug Corp

Recipient

Jan 15, 2026

PoP end

$107K

Obligated

$107K

Potential

424210

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

Federal

Contract numberSPE2DR26FP8QT

Also listed asSPE2DR25D3005-SPE2DR26FP8QT

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentAmerisourcebergen Drug Corp

CAGE1XUY5

UEIKABZK8W6PQT3

NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DR25D3005

Place of performanceCONSHOHOCKEN PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJan 14, 2026

PoP end (current)Jan 15, 2026

Obligated$107K

Current value$107K

Potential value$107K

4570517537!COSENTYX UNOREADY 300 MG PEN 2ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $107K ($107K obligated). Current period of performance ends Jan 15, 2026. Place of performance: CONSHOHOCKEN PA.

4570517537!COSENTYX UNOREADY 300 MG PEN 2ML

Recompete timing

Public

● Past PoP end (218 days ago)

Current PoP ended Jan 15, 2026 (218 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies

Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%

Open full company profile →

Related awards

Same parent · incumbent

36C77026P0121

DROSPIRENONE

$321K

Sep 27, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DR26FP8QT?

SPE2DR26FP8QT (4570517537!cosentyx unoready 300 MG PEN 2ml) is a Dla Troop Support award with a potential value of $107K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DR26FP8QT?

Dla Troop Support awarded SPE2DR26FP8QT to Amerisourcebergen Drug Corp (potential $107K).

Who is the incumbent on SPE2DR26FP8QT?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Jan 15, 2026.

When does Amerisourcebergen Drug Corp’s SPE2DR26FP8QT come up for recompete?

SCOUT tracks a period-of-performance end of Jan 15, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 11, 2026 · refreshed monthlyLatest procurement action Jan 14, 2026